Michael Borre

List of Publications by Citations

214 papers	7,517 citations	46 h-index	80 g-index
220 ext. papers	9,221 ext. citations	6 avg, IF	5.65 L-index

#	Paper	IF	Citations
214	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340
213	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. *Cancer Cell*, **2016**, 30, 27-42	24.3	325
212	Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. *Cancer Research*, **2009**, 69, 4851-60	10.1	320
211	Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. *International Journal of Cancer*, **2011**, 128, 1327-34	7.5	301
210	A dual program for translation regulation in cellular proliferation and differentiation. *Cell*, **2014**, 158, 1281-1292	56.2	278
209	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. *Nature Genetics*, **2011**, 43, 785-91	36.3	243
208	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. *Lancet Oncology, The*, **2008**, 9, 342-51	21.7	225
207	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *European Urology*, **2017**, 71, 151-154	10.2	202
206	Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. *Cancer Research*, **2014**, 74, 5758-71	10.1	195
205	Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. *Molecular and Cellular Proteomics*, **2008**, 7, 1214-24	7.6	174
204	Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. *Clinical Cancer Research* , **2011**, 17, 5582-92	12.9	146
203	Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. *European Urology*, **2009** , 55, 1112-23	10.2	125
202	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. *European Urology*, **2016**, 70, 75-82	10.2	123
201	miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. *Oncogene*, **2010**, 29, 1073-84	9.2	123
200	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Human Molecular Genetics*, **2013**, 22, 408-15	5.6	109
199	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. *Journal of Clinical Oncology*, **2019**, 37, 1051-1061	2.2	104
198	Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. *European Urology*, **2014**, 65, 704-9	10.2	103

197	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 3250-8	2.2	102
196	Mutational context and diverse clonal development in early and late bladder cancer. *Cell Reports*, **2014**, 7, 1649-1663	10.6	94
195	Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. *International Journal of Cancer*, **2012**, 131, 2320-31	7.5	91
194	Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. *Scandinavian Journal of Urology*, **2015**, 49, 133-41	1.6	86
193	Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. *PLoS ONE*, **2012**, 7, e46297	3.7	86
192	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. *Journal of Clinical Oncology*, **2018**, 36, 2639-2646	2.2	85
191	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. *BJU International*, **2010**, 106, 966-73	5.6	81
190	miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. *BMC Medical Genomics*, **2012**, 5, 40	3.7	77
189	Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. *BJU International*, **2012**, 110, E1228-36	5.6	77
188	Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. *Clinical Cancer Research*, **2014**, 20, 2169-81	12.9	74
187	Profiling of circulating microRNAs for prostate cancer biomarker discovery. *Drug Delivery and Translational Research*, **2014**, 4, 19-30	6.2	70
186	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. *Cancer Research*, **2016**, 76, 5894-5906	10.1	65
185	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
184	Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. *Clinical Cancer Research*, **2006**, 12, 807-12	12.9	61
183	Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. *American Journal of Pathology*, **2012**, 180, 1824-34	5.8	60
182	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. *Lancet Oncology, The*, **2014**, 15, 592-600	21.7	59
181	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57
180	Benzoxazinoids: Cereal phytochemicals with putative therapeutic and health-protecting properties. *Molecular Nutrition and Food Research*, **2015**, 59, 1324-38	5.9	56

179	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. *Scandinavian Journal of Urology*, **2014**, 48, 268-75	1.6	56
178	Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. *American Journal of Pathology*, **2013**, 182, 339-49	5.8	56
177	Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. *European Urology Focus*, **2018**, 4, 825-833	5.1	55
176	Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. *Scientific Reports*, **2015**, 5, 16018	4.9	53
175	Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. *Oncotarget*, **2016**, 7, 30760-71	3.3	53
174	Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways-secondary results from a randomized controlled trial. *Supportive Care in Cancer*, **2016**, 24, 3325-31	3.9	52
173	Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. *Journal of Clinical Oncology*, **2017**, 35, 3290-3297	2.2	49
172	Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. *BMC Cancer*, **2010**, 10, 646	4.8	48
171	The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. *BJU International*, **2011**, 107, 1426-31	5.6	47
170	Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. *British Journal of Cancer*, **2007**, 96, 499-506	8.7	47
169	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1121-9	4	46
168	Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. *BJU International*, **2012**, 110, E287-92	5.6	46
167	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. *Modern Pathology*, **2012**, 25, 902-10	9.8	44
166	Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. *International Journal of Cancer*, **2010**, 127, 1857-65	7.5	44
165	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure **1997**, 80, 917-928		44
164	Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. *Journal of Urology*, **1998**, 159, 1609-14	2.5	41
163	Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. *Journal of Multidisciplinary Healthcare*, **2014**, 7, 301-11	2.8	40
162	Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. *International Journal of Cancer*, **2009**, 125, 2095-103	7.5	40

161	Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. *Cancer Epidemiology*, **2014**, 38, 42-7	2.8	37
160	External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1804-12	4	37
159	Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. *British Journal of Cancer*, **2013**, 108, 420-8	8.7	37
158	Snail1 is over-expressed in prostate cancer. *Apmis*, **2009**, 117, 196-204	3.4	37
157	Diagnostic and Therapeutic Strategies for Prostate Cancer. *Seminars in Nuclear Medicine*, **2016**, 46, 484-490	3.4	37
156	A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy. *Journal of Medical Economics*, **2011**, 14, 403-9	2.4	36
155	p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. *Journal of Urology*, **2000**, 164, 716-721	2.5	34
154	Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. *Molecular Oncology*, **2018**, 12, 545-560	7.9	32
153	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. *Molecular Oncology*, **2016**, 10, 1450-1460	7.9	32
152	Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. *Apmis*, **1998**, 106, 463-9	3.4	32
151	Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerve-sparing radical prostatectomy: a randomized, controlled trial. *BJU International*, **2014**, 114, 111-7	5.6	31
150	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. *Oncotarget*, **2016**, 7, 74734-74746	3.3	31
149	The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. *Journal of Urology*, **2009**, 182, 35-40; discussion 40	2.5	29
148	Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. *Urology*, **2008**, 72, 1258-62	1.6	29
147	Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. *BJU International*, **2016**, 118, 646-53	5.6	28
146	High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression. *BMC Cancer*, **2009**, 9, 385	4.8	28
145	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. *Lancet, The*, **2021**, 398, 131-142	40	27
144	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. *Sports Medicine*, **2019**, 49, 145-158	10.6	27

143	Internet-delivered mindfulness-based cognitive therapy for anxiety and depression in cancer survivors: A randomized controlled trial. *Psycho-Oncology*, **2020**, 29, 68-75	3.9	26
142	Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. *Scientific Reports*, **2017**, 7, 40636	4.9	25
141	Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. *Apmis*, **2002**, 110, 177-85	3.4	25
140	Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 214-220	8.9	25
139	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. *European Urology*, **2015**, 68, 787-94	10.2	24
138	Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. *International Journal of Cancer*, **2015**, 136, 435-42	7.5	24
137	Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. *Clinical Epigenetics*, **2018**, 10, 105	7.7	24
136	High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. *Clinical Epigenetics*, **2015**, 7, 111	7.7	24
135	High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. *BMC Cancer*, **2014**, 14, 859	4.8	24
134	Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. *Urology*, **2010**, 75, 393-8	1.6	24
133	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. *PLoS Medicine*, **2019**, 16, e1002936	11.6	23
132	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. *European Urology*, **2018**, 73, 870-876	10.2	23
131	Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. *Clinical Cancer Research*, **2009**, 15, 1400-10	12.9	23
130	The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies. *Acta Oncologica*, **1997**, 36, 681-7	3.2	21
129	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. *Prostate*, **1998**, 36, 244-9	4.2	21
128	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. *International Journal of Cancer*, **2012**, 130, 885-95	7.5	20
127	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. *Oncotarget*, **2017**, 8, 5774-5788	3.3	20
126	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. *BMC Cancer*, **2014**, 14, 638	4.8	20

125	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. *Cancer Causes and Control*, **2016**, 27, 1067-79	2.8	20
124	Aberrant , , and Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	19
123	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. *Molecular Oncology*, **2016**, 10, 825-37	7.9	18
122	Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients. *Annals of Oncology*, **2018**, 29, 2003-2009	10.3	18
121	Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011. *Cancer*, **2015**, 121, 3692-9	6.4	18
120	Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer. *International Journal of Cancer*, **2008**, 122, 509-19	7.5	18
119	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	17
118	A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine. *International Journal of Cancer*, **2019**, 145, 2558-2567	7.5	16
117	Quality of urological cancer diagnoses in the Danish National Registry of Patients. *European Journal of Cancer Prevention*, **2012**, 21, 545-51	2	16
116	Secretagogin is a new neuroendocrine marker in the human prostate. *Prostate*, **2007**, 67, 472-84	4.2	16
115	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. *American Journal of Pathology*, **2019**, 189, 2377-2388	5.8	15
114	Quantitative Tumor Perfusion Imaging with Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. *Journal of Nuclear Medicine*, **2019**, 60, 1059-1065	8.9	15
113	Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. *BJU International*, **2014**, 113, 541-7	5.6	15
112	Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009. *Clinical Epidemiology*, **2012**, 4 Suppl 2, 17-23	5.9	15
111	Salvage radiation therapy following radical prostatectomy. A national Danish study. *Acta Oncologica*, **2016**, 55, 598-603	3.2	15
110	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model () for Prostate Cancer in Cell-Free Urine. *Clinical Chemistry*, **2019**, 65, 540-548	5.5	14
109	Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. *Scandinavian Journal of Urology*, **2016**, 50, 330-7	1.6	14
108	Home-based ®exergaming® was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial. *BJU International*, **2019**, 124, 600	5.6	13

107	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. *Clinical Epidemiology*, **2014**, 6, 351-7	5.9	13
106	Oncological outcomes and complication rates after laparoscopic-assisted cryoablation: a European Registry for Renal Cryoablation (EuRECA) multi-institutional study. *BJU International*, **2017**, 119, 390-395	5.6	12
105	Completeness of bladder cancer staging in the Danish Cancer Registry, 2004-2009. *Clinical Epidemiology*, **2012**, 4 Suppl 2, 25-31	5.9	12
104	Urethral pressure profile 6 months after radical prostatectomy may be diagnostic of sphincteric incontinence: preliminary data after 12 months follow-up. *Scandinavian Journal of Urology and Nephrology*, **2009**, 43, 114-8		12
103	Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. *Diagnostics*, **2020**, 10,	3.8	12
102	Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study. *Scandinavian Journal of Urology*, **2018**, 52, 8-13	1.6	12
101	A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise. *Trials*, **2017**, 18, 20	2.8	11
100	Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). *Cancer Epidemiology*, **2019**, 59, 249-257	2.8	11
99	Computed Tomography Contrast Enhancement Following Renal Cryoablation--Does it Represent Treatment Failure?. *Journal of Endourology*, **2015**, 29, 1353-60	2.7	11
98	Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. *Acta Radiologica*, **2018**, 59, 619-626	2	11
97	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. *Journal of Urology*, **2018**, 199, 459-464	2.5	11
96	Parkinson's disease and risk of prostate cancer: A Danish population-based case-control study, 1995-2010. *Cancer Epidemiology*, **2016**, 45, 157-161	2.8	11
95	Postoperative C-reactive protein concentration and clinical outcome: comparison of open cystectomy to robot-assisted laparoscopic cystectomy with extracorporeal or intracorporeal urinary diversion in a prospective study. *Scandinavian Journal of Urology*, **2017**, 51, 381-387	1.6	11
94	Survival of prostate cancer patients in central and northern Denmark, 1998-2009. *Clinical Epidemiology*, **2011**, 3 Suppl 1, 41-6	5.9	11
93	FRMD6 has tumor suppressor functions in prostate cancer. *Oncogene*, **2021**, 40, 763-776	9.2	11
92	Benzoxazinoids in Prostate Cancer Patients after a Rye-Intensive Diet: Methods and Initial Results. *Journal of Agricultural and Food Chemistry*, **2016**, 64, 8235-8245	5.7	10
91	Perioperative Systemic Inflammatory Response following Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study. *Urologia Internationalis*, **2017**, 99, 436-445	1.9	10
90	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. *BJU International*, **2015**, 115, 163-5	5.6	10

89	Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. *Journal of Urology*, **2019**, 201, 520-527	2.5	10
88	p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. *Journal of Urology*, **2000**, 164, 716-21	2.5	10
87	A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy. *International Journal of Cancer*, **2019**, 145, 3445-3452	7.5	9
86	Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry. *Clinical Epidemiology*, **2012**, 4, 145-9	5.9	9
85	Comorbidity and survival of Danish prostate cancer patients from 2000-2011: a population-based cohort study. *Clinical Epidemiology*, **2013**, 5, 47-55	5.9	9
84	Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure. *Scandinavian Journal of Urology and Nephrology*, **2011**, 45, 91-6		9
83	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 5006-5006	2.2	9
82	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). *Cancer Epidemiology*, **2020**, 64, 101623	2.8	9
81	Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. *Annals of Internal Medicine*, **2019**, 170, 443-452	8	9
80	Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. *Cancer Epidemiology*, **2015**, 39, 623-32	2.8	8
79	Scandinavian Prostate Cancer PatientsR Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment. *Sexual Medicine*, **2018**, 6, 210-216	2.7	8
78	Changes in preoperative characteristics in patients undergoing radical prostatectomy--a 16-year nationwide analysis. *Acta Oncologica*, **2014**, 53, 361-7	3.2	8
77	Efficacy of tele-nursing consultations in rehabilitation after radical prostatectomy: a randomised controlled trial study. *International Journal of Urological Nursing*, **2011**, 5, 123-130	0.8	8
76	The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. *BMC Cancer*, **2011**, 11, 519	4.8	8
75	Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. *BJU International*, **2009**, 104, 205-8	5.6	8
74	Body mass index and prognostic markers at radical prostatectomy. *Scandinavian Journal of Urology and Nephrology*, **2008**, 42, 230-6		8
73	Epigenetic silencing of MEIS2 in prostate cancer recurrence. *Clinical Epigenetics*, **2019**, 11, 147	7.7	7
72	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, e814-e821	3.3	7

71	Long-term Somatic Disease Risk in Adult Danish Cancer Survivors. *JAMA Oncology*, **2019**, 5, 537-545	13.4	7
70	Non-invasive quantification of tumor blood flow in prostate cancer using O-HO PET/CT. *American Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 8, 292-302	2.2	7
69	The Impact of HusbandsRProstate Cancer Diagnosis and Participation in a Behavioral Lifestyle Intervention on SpousesRLives and Relationships With Their Partners. *Cancer Nursing*, **2016**, 39, E1-9	2.6	7
68	Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. *Acta Oncol□gica*, **2016**, 55, 611-8	3.2	7
67	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. *Journal of Pathology*, **2021**, 255, 155-165	9.4	7
66	Computed Tomography Perfusion, Magnetic Resonance Imaging, and Histopathological Findings After Laparoscopic Renal Cryoablation: An In Vivo Pig Model. *Technology in Cancer Research and Treatment*, **2017**, 16, 406-413	2.7	6
65	Patient comorbidity is associated with conservative treatment of localized prostate cancer. *Scandinavian Journal of Urology*, **2015**, 49, 366-70	1.6	6
64	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. *Cells*, **2020**, 9,	7.9	6
63	Preoperative Aspects and Dimensions Used for Anatomical Score Predicts Treatment Failures in Laparoscopic Cryoablation of Small Renal Masses. *Journal of Endourology*, **2016**, 30, 537-43	2.7	6
62	Association between in vivo iododeoxyuridine labeling, MIB-1 expression, malignancy grade and clinical stage in human prostate cancer. *Apmis*, **1998**, 106, 389-95	3.4	6
61	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.. *Journal of Clinical Oncology*, **2016**, 34, 5001-5001	2.2	6
60	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2017**, 35, 5004-5004	2.2	6
59	Preoperative Nutritional Status And the Impact on Radical Cystectomy Recovery: An International Comparative Study. *Urologic Nursing*, **2016**, 36, 133	1.3	6
58	Bioactive small molecules in commercially available cereal food: Benzoxazinoids. *Journal of Food Composition and Analysis*, **2017**, 64, 213-222	4.1	6
57	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. *Oncogene*, **2021**, 40, 2437-2447	9.2	6
56	Arterial Clamping Increases Central Renal Cryoablation Efficacy: An Animal Study. *Technology in Cancer Research and Treatment*, **2017**, 16, 414-420	2.7	5
55	Repeatability of tumor blood flow quantification with Rubidium PET/CT in prostate cancer□a test-retest study. *EJNMMI Research*, **2019**, 9, 58	3.6	5
54	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. *Scandinavian Journal of Urology*, **2018**, 52, 20-26	1.6	5

53	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor is not expressed. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 503-13	2	5
52	Erythrocyte sedimentation rate--a predictor of malignant potential in early prostate cancer. *Acta Oncologica*, **1997**, 36, 689-94	3.2	5
51	Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situ in the urinary bladder. *BMC Cancer*, **2008**, 8, 37	4.8	5
50	The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care. *Acta Oncologica*, **2020**, 59, 1343-1356	3.2	5
49	Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases. *British Journal of Cancer*, **2018**, 119, 1527-1537	8.7	5
48	Soluble HER3 predicts survival in bladder cancer patients. *Oncology Letters*, **2018**, 15, 1783-1788	2.6	4
47	Shared care in prostate cancer: a three-year follow-up. *Scandinavian Journal of Urology*, **2016**, 50, 346-51	1.6	4
46	Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study. *BMC Family Practice*, **2018**, 19, 32	2.6	4
45	Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's letter to the editor Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. *European Urology*, **2013**, 64, e61	10.2	4
44	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. *Scandinavian Journal of Urology*, **2017**, 51, 457-463	1.6	4
43	The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. *American Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 9, 185-192	2.2	4
42	The Danish Prostate Cancer Database. *Clinical Epidemiology*, **2016**, 8, 649-653	5.9	4
41	Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na/K-ATPase-density. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 532-542	8.8	4
40	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure **1997**, 80, 917		4
39	Shared care is a model for patients with stable prostate cancer. *Danish Medical Journal*, **2013**, 60, A4691	3.8	4
38	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
37	Outpatient endoscopic treatment of ureteric stones: Five years' experience in a self-contained outpatient surgery unit. *Scandinavian Journal of Urology*, **2015**, 49, 395-9	1.6	3
36	Percentage of tumour-positive biopsy cores: an independent predictor of extraprostatic disease. *Scandinavian Journal of Urology and Nephrology*, **2009**, 43, 109-13		3

35	Improved survival of patients with prostate cancer in northern Denmark, 1985-2004. *Scandinavian Journal of Urology and Nephrology*, **2007**, 41, 308-13		3
34	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. *Frontiers in Oncology*, **2021**, 11, 631021	5.3	3
33	Internet-delivered Mindfulness-Based Cognitive Therapy for anxiety and depression in cancer survivors: Predictors of treatment response. *Internet Interventions*, **2021**, 23, 100365	4.4	3
32	Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy. *Journal of Urology*, **2021**, 206, 604-612	2.5	3
31	Molecular imaging of cholinergic processes in prostate cancer using □□C-donepezil and □□F-FEOBV. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 906-910	8.8	2
30	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. *Scientific Reports*, **2020**, 10, 10704	4.9	2
29	Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience. *Scandinavian Journal of Urology*, **2014**, 48, 27-33	1.6	2
28	Prostate cancer: to scan or not to scan for lymph node involvement?. *Scandinavian Journal of Urology and Nephrology*, **2007**, 41, 501-6		2
27	Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 62-62	2.2	2
26	Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. *Cancer Causes and Control*, **2020**, 31, 139-151	2.8	2
25	Renal cryoablation - does deep endophytic ablation affect the renal collecting system?. *Scandinavian Journal of Urology*, **2020**, 54, 33-39	1.6	2
24	Positive Predictive Value of Benign Prostatic Hyperplasia and Acute Urinary Retention in the Danish National Patient Registry: A Validation Study. *Clinical Epidemiology*, **2020**, 12, 1281-1285	5.9	2
23	Renal cryoablation: five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma. *Scandinavian Journal of Urology*, **2020**, 54, 408-412	1.6	2
22	Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial. *Sports Medicine - Open*, **2021**, 7, 27	6.1	2
21	Renal Potassium Excretion Visualized on Rubidium PET/CT. *Nuclear Medicine and Molecular Imaging*, **2020**, 54, 120-122	1.9	2
20	Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. *EJNMMI Research*, **2021**, 11, 12	3.6	2
19	Phased array magnetic resonance imaging for staging clinically localised prostrate cancer. *Acta Oncologica*, **2005**, 44, 589-92	3.2	2
18	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. *Scandinavian Journal of Urology*, **2015**, 49, 275-81	1.6	1

17	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by Ga-PSMA PET/CT.. *Diagnostics*, **2022**, 12,	3.8	1
16	Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling.. *Genome Medicine*, **2022**, 14, 9	14.4	1
15	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer.. *Genome Medicine*, **2022**, 14, 8	14.4	1
14	Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer. *Open Journal of Urology*, **2012**, 02, 38-44	0.2	1
13	Prostate Cancer Screening-The Need for and Clinical Relevance of Decision Analytical Models. *JAMA Network Open*, **2021**, 4, e212182	10.4	1
12	Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO-pneumoperitoneum in an experimental porcine study. *Scandinavian Journal of Urology*, **2018**, 52, 249-255	1.6	1
11	Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study. *Scandinavian Journal of Urology*, **2017**, 51, 50-56	1.6	0
10	Acute urinary retention and risk of cancer: population based Danish cohort study. *BMJ, The*, **2021**, 375, n2305	5.9	0
9	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.. *BMJ Open*, **2022**, 12, e050264	3	0
8	Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.. *Journal of Clinical Oncology*, **2018**, 36, 30-30	2.2	
7	Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 5068-5068	2.2	
6	Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis.. *Journal of Clinical Oncology*, **2015**, 33, e16096-e16096	2.2	
5	Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results.. *Journal of Clinical Oncology*, **2017**, 35, 220-220	2.2	
4	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. *BJU International*, **2021**, 128, 702-712	5.6	
3	Danish multidisciplinary cancer groups - DMCG.dk benchmarking consortium: Article series on cancer survival and mortality in Denmark 1995-2012. *Acta Oncologica*, **2016**, 55 Suppl 2, 1	3.2	
2	Reply to M. Nayan et al. *Journal of Clinical Oncology*, **2018**, 36, 629-630	2.2	
1	An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method.. *Scientific Reports*, **2022**, 12, 5260	4.9	